| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YGYNO.2012.06.034 |
| P8608 | Fatcat ID | release_sntkmwx3nng53oxbddn6szghuq |
| P698 | PubMed publication ID | 22765965 |
| P50 | author | Bradley J. Monk | Q107013145 |
| P2093 | author name string | Jan B Vermorken | |
| Thomas J Herzog | |||
| Carolyn N Krasner | |||
| Antonio Nieto | |||
| Stanley B Kaye | |||
| Andres Poveda | |||
| Pilar Lardelli Claret | |||
| Trilok Parekh | |||
| Youn Choi Park | |||
| P2860 | cites work | Use of Patient-Reported Outcomes in Randomized, Double-Blind, Placebo-Controlled Clinical Trials | Q24289168 |
| The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology | Q29615701 | ||
| Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. | Q30358112 | ||
| Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials | Q30434513 | ||
| Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group | Q31962966 | ||
| Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results | Q33332312 | ||
| Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 | ||
| Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial | Q34413664 | ||
| Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval | Q34413670 | ||
| Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer | Q34546077 | ||
| Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. | Q34552660 | ||
| Quality-of-life issues in the management of epithelial ovarian cancer | Q37049160 | ||
| Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment | Q37269617 | ||
| Quality of life in patients with ovarian cancer: current state of research | Q39465503 | ||
| Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer | Q40673230 | ||
| Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost | Q40828663 | ||
| Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. | Q43048172 | ||
| Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. | Q43953023 | ||
| An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer | Q47805126 | ||
| Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. | Q53252193 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. | Q53298171 | ||
| Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. | Q53500222 | ||
| Test-retest reliability of health state valuations collected with the EuroQol questionnaire. | Q53655098 | ||
| Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. | Q53657259 | ||
| Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer | Q59647328 | ||
| A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians | Q79830971 | ||
| Ovarian cancer | Q84605146 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| ovarian cancer | Q172341 | ||
| patient | Q181600 | ||
| P304 | page(s) | 161-167 | |
| P577 | publication date | 2012-07-02 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone | |
| P478 | volume | 127 |
| Q34898364 | Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models |
| Q36728989 | Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer |
| Q33921802 | Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence. |
| Q38255906 | Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics |
| Q36332234 | Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy - General mapping algorithms |
| Q57058665 | Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis |
| Q38728270 | Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line. |
| Q36382337 | Limitations to the use of carboplatin-based therapy in advanced ovarian cancer |
| Q26746924 | Marine Invertebrate Metabolites with Anticancer Activities: Solutions to the "Supply Problem" |
| Q92495346 | Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets |
| Q33705743 | Measuring symptoms as a critical component of drug development and evaluation in hematological diseases |
| Q38160258 | Optimizing treatment of the partially platinum-sensitive ovarian cancer patient |
| Q24201282 | Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer |
| Q34187661 | Pegylated liposomal doxorubicin in the management of ovarian cancer |
| Q47096976 | Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline |
| Q64239576 | TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers |
| Q34721579 | Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin - activity against ovarian cancer cells. |
| Q47903356 | Update on relapsed ovarian cancer treatment: from new consensus to daily clinical practice |
| Q36929772 | Updates on drug discovery in ovarian cancer |
| Q47903322 | When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer |
Search more.